4-氯-6,7-二氢-5H-吡咯并[2,3-d]嘧啶 | 16372-08-0

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 中文名称: 4-氯-6,7-二氢-5H-吡咯并[2,3-d]嘧啶
• 中文别名: 4-氯-6,7-二氢-5H-吡咯并[2,3-D]嘧啶
• 英文名称: 4-chloro-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine
• CAS: 16372-08-0
• 化学式: C₆H₆ClN₃
• mdl: MFCD11518925
• 分子量: 155.587
• InChiKey: LJXVPXRXXVHTBP-UHFFFAOYSA-N

物化性质

• 熔点：
  158.5-160 °C
• 沸点：
  252.4±50.0 °C(Predicted)
• 密度：
  1.63±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

反应信息

• 作为反应物：
  描述：

  4-氯-6,7-二氢-5H-吡咯并[2,3-d]嘧啶 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 锌 作用下， 以 N,N-二甲基乙酰胺 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.83h， 生成 (R)-7-(3-(2-fluorophenoxy)-2-hydroxy-2-methylpropanoyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine-4-carbonitrile
  参考文献：
  名称：

  1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators

  摘要：

  We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.

  DOI：

  10.1021/jm401625b
• 作为产物：
  描述：

  [2-(4,6-Dichloro-pyrimidin-5-yl)-ethyl]-(4-methoxy-benzyl)-amine 在 potassium phosphate 、 三氟乙酸 作用下， 以 二甲基亚砜 为溶剂， 反应 16.17h， 生成 4-氯-6,7-二氢-5H-吡咯并[2,3-d]嘧啶
  参考文献：
  名称：

  1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators

  摘要：

  We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.

  DOI：

  10.1021/jm401625b

文献信息

• COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
  申请人：Ibrahim Prabha N.

  公开号：US20090286783A1

  公开（公告）日：2009-11-19

  Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described. In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof derivatives thereof, forms thereof are active on at least one Raf protein kinase. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of Raf protein kinases, including melanoma, colorectal cancer, thyroid cancer, ovarian cancer, cholangiocarcinoma, pain or polycystic kidney disease.

  描述了化合物及其盐、配方、共轭物、衍生物、形式和用途。在某些方面和实施例中，所述化合物或其盐、配方、共轭物、衍生物、形式对至少一种Raf蛋白激酶具有活性。还描述了利用这些方法来治疗疾病和症状，包括与Raf蛋白激酶活性相关的疾病和症状，如黑色素瘤、结直肠癌、甲状腺癌、卵巢癌、胆管癌、疼痛或多囊肾病。
• [EN] CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE<br/>[FR] CERTAINES PYRIMIDINES SUBSTITUÉES, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BIOGEN IDEC INC

  公开号：WO2010117425A1

  公开（公告）日：2010-10-14

  Provided are certain Hsp90 inhibitors, i.e., compounds of Formula I and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods for their use and preparation.

  提供了某些Hsp90抑制剂，即Formula I的化合物及其药用盐、药物组合物以及它们的使用和制备方法。
• Purine compounds
  申请人：Gundersen Lise-Lotte

  公开号：US20070203159A1

  公开（公告）日：2007-08-30

  The invention provides an antimycobacterial 6-aryl-9-(m- or p-substituted-benzyl) purine and purine analog compounds.

  这项发明提供了一种抗分枝杆菌的6-芳基-9-(m-或p-取代苄基)嘌呤和嘌呤类似化合物。
• [EN] IL-17A MODULATORS<br/>[FR] MODULATEURS DE IL-17A
  申请人：SANOFI SA

  公开号：WO2021239743A1

  公开（公告）日：2021-12-02

  The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.

  本发明涉及一种IL-17A调节剂化合物。这些化合物具有本文中定义的结构式I。本发明还涉及制备这些化合物的方法，包括它们的药物组成物，以及它们在治疗与IL-17A活性调节相关的疾病或疾病中的用途。
• [EN] NOVEL HETEROCYCLIC DERIVATIVES AS MODULATORS OF KINASE ACTIVITY<br/>[FR] NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES COMME MODULATEURS DE L'ACTIVITÉ KINASE
  申请人：MERCK PATENT GMBH

  公开号：WO2014078637A1

  公开（公告）日：2014-05-22

  The invention provides novel imidazol-piperidinyl derivatives of the formula (I) in which R1, R2, W, X1, X2, X3, X4 and n have the meanings indicated in formula (I), and their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

  该发明提供了公式（I）中的新型咪唑-哌啶衍生物，其中R1、R2、W、X1、X2、X3、X4和n具有公式（I）中所示的含义，并且它们的制造和用于治疗高增殖性疾病，如癌症。